Changes of bone turnover markers and bone mineral density among postmenopausal Thai women with osteoporosis receiving generic risedronate
Postmenopausal women with osteoporosis who were treated with generic risedronate demonstrated significant suppression of the bone remodelling process at 3, 6, and 12 months after treatment initiation. Additionally, significant improvements in the lumbar spine, femoral neck, and total hip BMD were observed at 12 months of therapy. These findings suggest that generic risedronate could be considered a reasonable and interesting option for treating postmenopausal women with osteoporosis in Thailand.
Authors
- Chavarin Amarase (ORCID: https://orcid.org/0000-0001-5249-3781)
- Ammarin Suwan (ORCID: https://orcid.org/0000-0002-8512-3071)
- Srihatach Ngarmukos (ORCID: https://orcid.org/0000-0002-3165-1143)
- Thanapob Bumphenkiatikul (ORCID: https://orcid.org/0000-0003-3311-8040)
- Krasean Panyakhamlerd (ORCID: https://orcid.org/0009-0003-2746-7524)
- Chotetawan Tanavalee (ORCID: https://orcid.org/0000-0001-9634-8893)
- Aree Tanavalee (ORCID: https://orcid.org/0000-0001-7007-7044)
- Suchanant Chavaengkiat
Institutions
- Chulalongkorn University (TH)
- King Chulalongkorn Memorial Hospital (TH)
Publication Details
- Journal
- BMC Women s Health
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1186/s12905-024-03404-5
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00